Overview
- Sector
Trading
- Industry
Trading - Medium / Small
- Market Cap
15 Cr
- Volatility
High Risk
- P/E Ratio
25.7
- Industry P/E
37.3
- PEG Ratio
0.7
- P/B Ratio
1.7
- 52W High
35.00
- 52W Low
16.00
Financial Ratios
Sales CAGR
- 1Y
- 2.93%
- 3Y
- 7.69%
- 5Y
- —
- 10Y
- —
Profit CAGR
- 1Y
- -40.00%
- 3Y
- 34.81%
- 5Y
- —
- 10Y
- —
ROE
- TTM
- -1.92%
- 3Y
- 8.57%
- 5Y
- —
- 10Y
- —
ROCE
- TTM
- 0.17%
- 3Y
- 11.40%
- 5Y
- —
- 10Y
- —
Financial Statements
AI Powered Summary
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Ask AI
Standalone Half Yearly Results (in ₹ Crores)
Standalone Profit Loss (in ₹ Crores)
Standalone Balance Sheet (in ₹ Crores)
Standalone Cash Flows (in ₹ Crores)
Documents
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI


Frequently Asked Questions about Hamps Bio Limited
Hamps Bio Limited (HAMPS) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Hamps Bio Limited is a company focused on ethical marketing and distribution of pharmaceutical and FMCG products, including pharma formulations and freeze-dried food items. The company was originally incorporated as a private entity in 2007 and transitioned to a public limited company in 2023, planning an IPO to expand its equity base. It operates a widespread distribution network with over 50 distributors and e-commerce platforms, selling pharmaceutical products in 8 Indian states and freeze-dried products in several countries. The company has diversified its offerings by launching an FMCG division, focusing on freeze dried and frozen products, under its brand 'FzyEzy' since 2017. Hamps Bio Limited's presence in the pharmaceutical industry is built through strategic partnerships with WHO GMP approved contract manufacturers, ensuring quality in its distributed products.
Over the past 52 weeks, Hamps Bio Limited has traded between a low of ₹0.00 and a high of ₹35.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Hamps Bio Limited has a market capitalization of approximately 15.25. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Hamps Bio Limited’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 25.74 and operates in the Trading sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 15.25 Cr, Hamps Bio Limited is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Hamps Bio Limited operates in the Trading sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Hamps Bio Limited is 25.74. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
